Acumen Pharmaceuticals, Inc.

General Information

We are a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer’s disease, or AD. Alzheimer’s disease is a progressive neurodegenerative disease of the brain that leads to loss of memory and cognitive functions and ultimately results in death. Our scientific founders pioneered research on soluble amyloid-beta oligomers, or AbOs, globular assemblies of the amyloid-beta, or Ab, peptide that are distinct from Ab monomers and amyloid plaques. Based on decades of research and supporting evidence, AbOs have gained increasing scientific acceptance as a primary toxin involved in the initiation and propagation of AD pathology.

We are currently focused on advancing a targeted immunotherapy drug candidate, ACU193, and establishing proof of mechanism in early AD patients. ACU193 is a humanized monoclonal antibody that selectively targets AbOs, has demonstrated functional and protective effects in in vitro assays, and has demonstrated in vivo safety and pharmacologic activity in multiple animal species including transgenic models for AD. We initiated our Phase 1 clinical trial of ACU193 in the second quarter of 2021 with the objective to evaluate its safety and tolerability and explore its pharmacokinetics and target engagement. This trial is enrolling patients with mild dementia or mild cognitive impairment, or MCI, due to AD, conditions referred to as “early AD.” Our ACU193 Phase 1 data intended to evaluate safety and tolerability and demonstrate clinical proof of mechanism are expected by year end 2022.

Note: Revenue is grant revenue for the year ended Dec.31, 2020. The net loss figure is also for 2020.

(Note: Acumen Pharmaceuticals upsized its IPO at pricing on June 30, 2021, to 9.99 million shares, up from 8.33 million in the prospectus, at $16 – the top of its $14-to-$16 range – to raise $159.84 million.)

Employees: 7
Founded: 1996
Contact Information
Address 427 Park St. Charlottesville, VA 22902
Phone Number (434) 297-1000
Web Address http://www.acumenpharm/
View Prospectus: Acumen Pharmaceuticals, Inc.
Financial Information
Market Cap $554.85mil
Revenues $1.44 mil (last 12 months)
Net Income $-7.33 mil (last 12 months)
IPO Profile
Symbol ABOS
Exchange NASDAQ
Shares (millions): 10.0
Price range $16.00 - $16.00
Est. $ Volume $159.8 mil
Manager / Joint Managers BofA Securities/ Credit Suisse/ Stifel
CO-Managers UBS Investment Bank
Expected To Trade: 7/1/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change